Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Psychiatric Quarterly
Published in: Psychiatric Quarterly 1/2019

01-03-2019 | Original Paper

Factors Affecting the Management of Somatic Comorbidity in Tunisian Patients with Schizophrenia

Authors: Jihene Ben Thabet, Nada Charfi, Wafa Dalhoum, Sourour Yaich, Manel Maâlej Bouali, Sana Omri, Nasreddine Zouari, Lobna Zouari, Jamel Damak, Mohamed Maâlej

Published in: Psychiatric Quarterly | Issue 1/2019

Login to get access

Abstract

Schizophrenia is often accompanied by somatic comorbidities, which make the management challenge of such patients more difficult. In this study, we proposed to identify the sociodemographic and clinical factors correlating with somatic comorbidities in patients with schizophrenia to facilitate screening and prevention. It was a retrospective descriptive study of 78 schizophrenia patients in clinical remission and followed in outpatient psychiatry. In addition to the acquired records, other data were provided by the clinical and biological examinations performed for each patient. The evaluation of the therapeutic adherence was carried out using the Drug Attitude Inventory (DAI).Seventy-six patients (97.4%) had somatic comorbidities with a mean of 3.83 (± 1.81). This number increased significantly in males, older patients, couples, urban patients, and those receiving a combination therapy. According to a multivariate study, the four predictors of an increased risk of comorbidities were age, use of psychoactive substances, waist size and therapeutic adherence.Our findings focus on somatic comorbidities risk in schizophrenia patients, requiring particular vigilance in their follow-up, and suggest some modifiable clinical factors that might be a preferred target for reducing or preventing the occurrence of such disorders.
Literature
1.
Janssen EM, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL. Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. Gen Hosp Psychiatry. 2015;37:199–222.CrossRefPubMedPubMedCentral
2.
Scott D, Happell B. The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues Ment Health Nurs. 2011;32:589–97.CrossRefPubMed
3.
Kilian R, Becker T. Physical illness and schizophrenia. A review of the evidence. J Psychosom Res. 2009;68:101–2.CrossRef
4.
Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–47.CrossRefPubMedPubMedCentral
5.
Montejo AL. The need for routine physical health care in schizophrenia. Eur Psychiat. 2010;25(2):S3–5.CrossRef
6.
Von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand. 2009;438:15–21.CrossRef
7.
Stjernswärd S, Persson K, Nielsen R, Tuninger E, Levander S. A modified drug attitude inventory used in long-term patients in sheltered housing. Eur Neuropsychopharmacol. 2013;23(10):1296–9.CrossRefPubMed
8.
Bahorik AL, Sartre DD, Kline-Simon AH, Weisner CM, Campbell CI. Serious mental illness and medical comorbidities: findings from an integrated health care system. J Psychosom Res. 2017;100:35–45.CrossRefPubMedPubMedCentral
9.
Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83–8.CrossRefPubMed
10.
Gabilondo A, Alonso-Moran E, Nuño-Solinis R, Orueta JF, Iruin A. Comorbidities with chronic physical conditions and gender profiles of illness in schizophrenia.Results from PREST, a new health dataset. J Psychosom Res. 2017;93:102–9.CrossRefPubMed
11.
Jones DR, Macias C, Barreria PJ, Fisher WH, Hargreaves WA, Harding CM. Prevalence, severity and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv. 2004;55:1250–7.CrossRefPubMedPubMedCentral
12.
Oud MJT, Meyboom de Jong B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract. 2009;10:32.CrossRefPubMedPubMedCentral
13.
Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open. 2013;17:3(4).
14.
Nash M. Diagnostic overshadowing: a potential barrier to physical health care for mental health service users. Ment Health Pract. 2013;17:22–3.CrossRef
15.
Kurzthaler L, Fleischhacker W. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62:32–7.PubMed
16.
17.
Roberts L, Roalfe A, Wilson S, Lester H. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract. 2007;24:34–40.CrossRefPubMed
18.
Wright CA, Osborn DPJ, Nazareth I, King MB. Prevention of coronary heart disease in people with severe mental illnesses: a qualitative study of patient and professionals' preferences for care. BMC Psychiatry. 2006;6:16.CrossRefPubMedPubMedCentral
19.
Eskelinen S, Sailas E, Joutsenniemi K, Holi M, Koskela TH, Suvisaari J. Multiple physical healthcare needs among outpatients with schizophrenia: findings from a health examination study. Nord J Psychiatry. 2017;71(6):448–54.CrossRefPubMed
20.
Carrà G, Johnson S, Bebbington P, Angermeyer MC, Heider D, Brugha T, et al. The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European schizophrenia cohort (EuroSC). Eur Arch Psychiatry Clin Neurosci. 2012;262(7):607–16.CrossRefPubMed
21.
Hamdan-Mansour A, Al-Sagarat A, AL-Sarayreh F, Nawafleh H, Arabiat DH. Prevalence and correlates of substance use among psychiatric inpatients. Perspect Psychiatr Care. 2017;17:1–7.
22.
Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini R. Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophr Res. 2006;86(1):251–5.CrossRefPubMed
23.
Favre JD. Schizophrénie et abus d’alcool : données cliniques. L'Encéphale. 2003;29:20–2.
24.
De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–57.CrossRefPubMed
25.
Myles N, Newall HD, Curtis J. Tobacco use before, at and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry. 2012;73:468–75.CrossRefPubMed
26.
Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115–21.CrossRefPubMed
27.
Dickerson F, Stallings C, Origoni A, Schroeder J, Khushalani S, Yolken R. Mortality in schizophrenia: clinical and serological predictors. Schizophr Bull. 2014;40(4):796–803.CrossRefPubMed
28.
Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatry Res. 2013;47:197–207.CrossRef
29.
Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia : a preliminary study. Schizophr Bull. 2003;29:393–7.CrossRefPubMed
30.
Bushe C, Haddad P, Peveler R, Pendlebury J. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol. 2005;19:28–35.CrossRefPubMed
31.
Ito H, Kumagai T, Kimura M, Koike S, Shimizu T. Dietary intake in body mass index differences in community-based Japanese patients with schizophrenia. Iran J Public Health. 2015;44:639–45.PubMedPubMedCentral
32.
33.
Heald A, Pendlebury J, Anderson S, Narayan V, Guy M, Gibson M, et al. Lifestyle factors and the metabolic syndrome in schizophrenia: a cross-sectional study. Ann General Psychiatry. 2017;16:12.CrossRef
34.
Jahrami HA, Faris MAE, Saif ZQ, Hammad LH. Assessing dietary and lifestyle risk factors and their associations with disease comorbidities among patients with schizophrenia: a case-control study from Bahrain. Asian J Psychiatr. 2017;28:115–23.CrossRefPubMed
35.
Stubbs B, Firth J, Berry A, Schuch FB, Rosenbaum S, Gaughran F, et al. How much physical activity do people with schizophrenia engage inA systematic review, comparative metaanalysis and metaregression. Schizophr Res. 2016;176:431–40.CrossRefPubMed
36.
Stubbs B, Williams J, Gaughran F, Craig T. How sedentary are people with psychosis? A systematic review and meta-analysis. Schizophr Res. 2016;171:103–9.CrossRefPubMed
37.
Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S. De HertM. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012;125:352–62.CrossRefPubMed
38.
Vancampfort D, Probst M, Scheewe T, De Herdt A, Sweers K, Knapen J, et al. Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia. Psychiatry Res. 2013;207(1–2):25–32.CrossRefPubMed
39.
Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatr 2012 ;25(5):415–429.
40.
Du Pan RM, Baumann P. Dysfonctions sexuelles induites par les antidépresseurs et les antipsychotiques et leurs traitements. Rev Med Suisse. 2008;4:758–62.
41.
Gourevitch R. Comment améliorer l’observance chez le patient souffrant de schizophrénie ? L'Encéphale. 2006;32:929–30.CrossRef
42.
Ben Mahmoud S, Zouari L, Dammak M, Ben Thabet J, Zouari N, Maâlej M. Evaluation of sexuality in 61 subjects suffering from chronic psychosis. Sexologies. 2013;22:90–6.
43.
Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39:295–305.CrossRefPubMed
Metadata
Title
Factors Affecting the Management of Somatic Comorbidity in Tunisian Patients with Schizophrenia
Authors
Jihene Ben Thabet
Nada Charfi
Wafa Dalhoum
Sourour Yaich
Manel Maâlej Bouali
Sana Omri
Nasreddine Zouari
Lobna Zouari
Jamel Damak
Mohamed Maâlej
Publication date
01-03-2019
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 1/2019
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-018-9605-4

Other articles of this Issue 1/2019

Psychiatric Quarterly 1/2019 Go to the issue

Original Paper

Sociodemographic Variation in Increasing Needs for Mental Health Services among Canadian Adults from 2002 to 2012

Review Article

Digitally Delivered Psychological Interventions for Anxiety Disorders: a Comprehensive Review

Original Paper

Do Home-Based Psychiatric Services for Patients in Medico-Social Institutions Reduce Hospitalizations? Pre-Post Evaluation of a French Psychiatric Mobile Team

Original Paper

Suicidal Thoughts, Attempts and Motives Among University Students in 12 Muslim-Majority Countries

Original Paper

Trauma Stabilisation as a Sole Treatment Intervention for Post-Traumatic Stress Disorder in Southeast Asia

Original Paper

Psychometric Testing of Three Chinese Online-Related Addictive Behavior Instruments among Hong Kong University Students